United States - English - NLM (National Library of Medicine)

cameron pharmaceuticals, llc - flucytosine (unii: d83282dt06) (flucytosine - unii:d83282dt06) - flucytosine 250 mg - flucytosine capsules are indicated only in the treatment of serious infections caused by susceptible strains of candida and/or cryptococcus . candida: septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. limited trials in pulmonary infections justify the use of flucytosine. cryptococcus: meningitis and pulmonary infections have been treated effectively. studies in septicemias and urinary tract infections are limited, but good responses have been reported. flucytosine capsules should be used in combination with amphotericin b for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to flucytosine capsules (see microbiology ). flucytosine capsules are contraindicated in patients with a known hypersensitivity to the drug. flucytosine capsules are contraindicated in patients with known complete dihydropyrimidine dehydrogenase (dpd) enzyme deficiency (see warnings ).

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - flucytosine (unii: d83282dt06) (flucytosine - unii:d83282dt06) - flucytosine 250 mg - flucytosine is indicated only in the treatment of serious infections caused by susceptible strains of candida and/or cryptococcus . candida: septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. limited trials in pulmonary infections justify the use of flucytosine. cryptococcus: meningitis and pulmonary infections have been treated effectively. studies in septicemias and urinary tract infections are limited, but good responses have been reported. flucytosine should be used in combination with amphotericin b for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to flucytosine (see microbiology) . flucytosine is contraindicated in patients with a known hypersensitivity to the drug. flucytosine is contraindicated in patients with known complete dihydropyrimidine dehydrogenase (dpd) enzyme deficiency (see warnings ).

United States - English - NLM (National Library of Medicine)

sigmapharm laboratories, llc - flucytosine (unii: d83282dt06) (flucytosine - unii:d83282dt06) - flucytosine capsules, usp are indicated only in the treatment of serious infections caused by susceptible strains of candida and/or cryptococcus . candida: septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. limited trials in pulmonary infections justify the use of flucytosine. cryptococcus: meningitis and pulmonary infections have been treated effectively. studies in septicemias and urinary tract infections are limited, but good responses have been reported. flucytosine capsules, usp should be used in combination with amphotericin b for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to flucytosine capsules, usp (see  microbiology). flucytosine capsules, usp should not be used in patients with a known hypersensitivity to the drug.

United States - English - NLM (National Library of Medicine)

american health packaging - flucytosine (unii: d83282dt06) (flucytosine - unii:d83282dt06) - flucytosine capsules usp is indicated only in the treatment of serious infections caused by susceptible strains of candida and/or cryptococcus . candida: septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. limited trials in pulmonary infections justify the use of flucytosine. cryptococcus: meningitis and pulmonary infections have been treated effectively. studies in septicemias and urinary tract infections are limited, but good responses have been reported. flucytosine capsules usp should be used in combination with amphotericin b for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to flucytosine capsules usp (see microbiology ). flucytosine capsules usp should not be used in patients with a known hypersensitivity to the drug.

United States - English - NLM (National Library of Medicine)

major pharmaceuticals - flucytosine (unii: d83282dt06) (flucytosine - unii:d83282dt06) - flucytosine capsules usp is indicated only in the treatment of serious infections caused by susceptible strains of candida and/or cryptococcus . candida: septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. limited trials in pulmonary infections justify the use of flucytosine. cryptococcus: meningitis and pulmonary infections have been treated effectively. studies in septicemias and urinary tract infections are limited, but good responses have been reported. flucytosine capsules usp should be used in combination with amphotericin b for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to flucytosine capsules usp (see microbiology). flucytosine capsules usp should not be used in patients with a known hypersensitivity to the drug.

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - flucytosine (unii: d83282dt06) (flucytosine - unii:d83282dt06) - flucytosine capsules are indicated only in the treatment of serious infections caused by susceptible strains of candida and/or cryptococcus . candida: septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. limited trials in pulmonary infections justify the use of flucytosine cryptococcus: meningitis and pulmonary infections have been treated effectively. studies in septicemias and urinary tract infections are limited, but good responses have been reported. flucytosine capsules should be used in combination with amphotericin b for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to flucytosine capsules (see microbiology ). flucytosine capsules should not be used in patients with a known hypersensitivity to the drug.

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - flucytosine (unii: d83282dt06) (flucytosine - unii:d83282dt06) - flucytosine capsules are indicated only in the treatment of serious infections caused by susceptible strains of candida and/or cryptococcus . candida: septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. limited trials in pulmonary infections justify the use of flucytosine cryptococcus: meningitis and pulmonary infections have been treated effectively. studies in septicemias and urinary tract infections are limited, but good responses have been reported. flucytosine capsules should be used in combination with amphotericin b for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to flucytosine capsules (see microbiology ). flucytosine capsules should not be used in patients with a known hypersensitivity to the drug.

United States - English - NLM (National Library of Medicine)

avpak - flucytosine (unii: d83282dt06) (flucytosine - unii:d83282dt06) - flucytosine capsules usp is indicated only in the treatment of serious infections caused by susceptible strains of candida and/or cryptococcus . candida: septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. limited trials in pulmonary infections justify the use of flucytosine. cryptococcus: meningitis and pulmonary infections have been treated effectively. studies in septicemias and urinary tract infections are limited, but good responses have been reported. flucytosine capsules usp should be used in combination with amphotericin b for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to flucytosine capsules usp (see microbiology). flucytosine capsules usp should not be used in patients with a known hypersensitivity to the drug.

United States - English - NLM (National Library of Medicine)

american health packaging - flucytosine (unii: d83282dt06) (flucytosine - unii:d83282dt06) - flucytosine capsules are indicated only in the treatment of serious infections caused by susceptible strains of candida and/or cryptococcus . candida: septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. limited trials in pulmonary infections justify the use of flucytosine. cryptococcus: meningitis and pulmonary infections have been treated effectively. studies in septicemias and urinary tract infections are limited, but good responses have been reported. flucytosine capsules should be used in combination with amphotericin b for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to flucytosine (see microbiology ). flucytosine capsules are contraindicated in patients with a known hypersensitivity to the drug. flucytosine capsules are contraindicated in patients with known complete dihydropyrimidine dehydrogenase (dpd) enzyme deficiency (see warnings ).

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - flucytosine (unii: d83282dt06) (flucytosine - unii:d83282dt06) - flucytosine capsules are indicated only in the treatment of serious infections caused by susceptible strains of candida and/or cryptococcus . candida: septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. limited trials in pulmonary infections justify the use of flucytosine cryptococcus: meningitis and pulmonary infections have been treated effectively. studies in septicemias and urinary tract infections are limited, but good responses have been reported. flucytosine capsules should be used in combination with amphotericin b for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to flucytosine capsules (see microbiology ). flucytosine capsules should not be used in patients with a known hypersensitivity to the drug.